Arkolith/Insider Trading/SABS/Form 4

King Michael

CHIEF FINANCIAL OFFICERSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4 · filed Nov 3, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 30, 2023Grant(A)850K—$0850K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-058894) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML